Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34092
Title: A Mouse Model for the Rapid and Binomial Assessment of Putative WNT/β-Catenin Signalling Inhibitors.
Austin Authors: Tse, Janson;O'Keefe, Ryan;Rigopolous, Angela;Carli, Annalisa L E;Waaler, Jo;Krauss, Stefan;Ernst, Matthias ;Buchert, Michael 
Affiliation: Olivia Newton-John Cancer Research Institute
School of Cancer Medicine, La Trobe University, Bundoora, VIC 3086, Australia.
Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, 0317 Oslo, Norway.
Department of Immunology and Transfusion Medicine, Oslo University Hospital, Rikshospitalet, 0424 Oslo, Norway.;Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, 0317 Oslo, Norway.
Issue Date: 7-Oct-2023
Date: 2023
Publication information: Biomedicines 2023-10-07; 11(10)
Abstract: Specific signalling thresholds of the WNT/β-catenin pathway affect embryogenesis and tissue homeostasis in the adult, with mutations in this pathway frequently occurring in cancer. Excessive WNT/β-catenin activity inhibits murine anterior development associated with embryonic lethality and accounts for the driver event in 80% of human colorectal cancers. Uncontrolled WNT/β-catenin signalling arises primarily from impairment mutation in the tumour suppressor gene APC that otherwise prevents prolonged stabilisation of β-catenin. Surprisingly, no inhibitor compounds for WNT/β-catenin signalling have reached clinical use in part owing to the lack of specific in vivo assays that discriminate between on-target activities and dose-limiting toxicities. Here, we present a simple in vivo assay with a binary outcome whereby the administration of candidate compounds to pregnant and phenotypically normal Apcflox/flox mice can rescue in utero death of Apcmin/flox mutant conceptus without subsequent post-mortem assessment of WNT/β-catenin signalling. Indeed, the phenotypic plasticity of born Apcmin/flox conceptus enables future refinement of our assay to potentially enable dosage finding and cross-compound comparisons. Thus, we show for the first time the suitability of endogenous WNT/β-catenin signalling during embryonic development to provide an unambiguous and sensitive mammalian in vivo model to assess the efficacy and bioavailability of potential WNT/β-catenin antagonists.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34092
DOI: 10.3390/biomedicines11102719
ORCID: 0000-0002-8527-2165
0000-0003-0312-1097
0000-0002-6399-1177
0000-0003-2672-0148
Journal: Biomedicines
PubMed URL: 37893093
Type: Journal Article
Subjects: APC
WNT inhibitors
WNT/β-catenin signalling
in vivo assay
pyrvinium pamoate
tankyrase inhibitor
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Dec 12, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.